Micafungin
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Micafungin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Micafungin, sold under the brand name Mycamine, is an echinocandin antifungal medication used to treat and prevent invasive fungal infections including candidemia, abscesses, and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls that is not found in mammals.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Mycamine |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99.8% |
Metabolism | Via catechol-O-methyltransferase pathway |
Elimination half-life | 11–17 hours |
Excretion | 40% feces, <15% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C56H71N9O23S |
Molar mass | 1270.28 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
Administered intravenously, Micafungin received final approval from the U.S. Food and Drug Administration (FDA) in March 2005, and gained approval in the European Union in April 2008. It is on the World Health Organization's List of Essential Medicines.[1]
In August 2023, Mycamine was acquired from Astellas Pharma by Sandoz.[2]